328 related articles for article (PubMed ID: 14667200)
1. Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Nuessler V; Schmetzer H
Eur J Haematol; 2003 Nov; 71(5):366-76. PubMed ID: 14667200
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
3. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Br J Haematol; 2001 Jan; 112(1):118-26. PubMed ID: 11167792
[TBL] [Abstract][Full Text] [Related]
4. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
[TBL] [Abstract][Full Text] [Related]
5. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
[TBL] [Abstract][Full Text] [Related]
6. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
[TBL] [Abstract][Full Text] [Related]
7. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
8. Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.
Hiçsönmez G; Cetin M; Tuncer AM; Yenicesu I; Aslan D; Ozyürek E; Unal S
Leuk Res; 2004 Jan; 28(1):25-34. PubMed ID: 14630077
[TBL] [Abstract][Full Text] [Related]
9. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
[TBL] [Abstract][Full Text] [Related]
11. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
12. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
[TBL] [Abstract][Full Text] [Related]
13. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
14. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
15. L and E selectins in acute myeloid leukemia: expression, clinical relevance and relation to patient outcome.
Aref S; Salama O; Al-Tonbary Y; Fouda M; Menessy A; El-Sherbiny M
Hematology; 2002 Apr; 7(2):83-7. PubMed ID: 12186696
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Grimwade D; Walker H; Harrison G; Oliver F; Chatters S; Harrison CJ; Wheatley K; Burnett AK; Goldstone AH;
Blood; 2001 Sep; 98(5):1312-20. PubMed ID: 11520776
[TBL] [Abstract][Full Text] [Related]
17. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
18. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
20. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
